A61K 40/418
Antigens related to induction of tolerance to non-self
Official title: {Antigens related to induction of tolerance to non-self}
A61K40/418 (Antigens related to induction of tolerance to non-self) appears on 362 US grants and 761 published applications in this corpus.
Search patents in A61K- Granted patents
- 362
- Published applications
- 761
- Assignees
- 368
- Inventors
- 1,164
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 5 | 0 |
| 1998 | 5 | 0 |
| 1999 | 4 | 0 |
| 2000 | 7 | 0 |
| 2001 | 6 | 3 |
| 2002 | 11 | 16 |
| 2003 | 5 | 19 |
| 2004 | 5 | 20 |
| 2005 | 3 | 12 |
| 2006 | 2 | 15 |
| 2007 | 5 | 10 |
| 2008 | 6 | 11 |
| 2009 | 6 | 15 |
| 2010 | 8 | 15 |
| 2011 | 9 | 25 |
| 2012 | 5 | 15 |
| 2013 | 7 | 17 |
| 2014 | 13 | 23 |
| 2015 | 7 | 29 |
| 2016 | 15 | 27 |
| 2017 | 18 | 29 |
| 2018 | 26 | 48 |
| 2019 | 15 | 47 |
| 2020 | 22 | 53 |
| 2021 | 24 | 56 |
| 2022 | 21 | 80 |
| 2023 | 25 | 55 |
| 2024 | 26 | 51 |
| 2025 | 28 | 40 |
| 2026 | 20 | 30 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Microparticle-assisted Treg therapy for treatment of tissue injury and fibrosis22 Sep 2026US 12,741,026 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- K562 universal antigen presenting cells and uses thereof15 Sep 2026US 12,734,239 B2Board of Regents, The University of Texas System
- Compositions and methods for hematopoietic stem cell transplants15 Sep 2026US 12,735,678 B2Orca Biosystems, Inc.
- Variant ICOS ligand immunomodulatory proteins and related compositions and methods28 Jul 2026US 12,692,299 B2Alpine Immune Sciences, Inc.
- Populations of enriched regulatory T cells and methods for producing same28 Jul 2026US 12,692,478 B2Cellenkos, Inc.
- Rapamycin resistant cells8 Oct 2026US 2026/0308637 A1Seattle Children's Hospital (dba Seattle Children's Research Institute)
- Methods for stem cell transplantation1 Oct 2026US 2026/0294975 A1The UAB Research Foundation
- Populations of enriched regulatory t cells and methods for producing same1 Oct 2026US 2026/0297523 A1Cellenkos, Inc.
- Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof3 Sep 2026US 2026/0256896 A1University of Washington through its Center for Commercialization
- Engineered t cells3 Sep 2026US 2026/0258104 A1Intellia Therapeutics, Inc.
Most cited
By later US patents
- High efficiency transduction of T lymphocytes using rapid expansion methods ("REM")235US 6,040,177 AFred Hutchinson Cancer Research Center · 2000
- CD19-specific chimeric T cell receptor231US 7,446,179 B2City of Hope · 2008
- Method of preparing suppressor T cells with allogeneic mesenchymal stem cells149US 6,281,012 B1Osiris Therapeutics, Inc. · 2001
- Rapid expansion method ("REM") for in vitro propagation of T lymphocytes106US 5,827,642 AFred Hutchinson Cancer Research Center · 1998
- Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation95US 6,685,936 B2Osiris Therapeutics, Inc. · 2004